pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
PARItec clinical programs — 248 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
PARItec projects
248 ClinicalTrials.gov programs sponsored by PARItec.
PARItec has 248 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
DONEPEZIL, DONEPEZIL
Pari Pharma GmbH
Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease
1 trial -
MEROPENEM AND VABORBACTAM for Pyogenic liver abscess
Pari Pharma GmbH
Pyogenic liver abscess
1 trial -
MUCODRILL for Ultra High Risk of psychosis an…
Pari Pharma GmbH
Ultra High Risk of psychosis and first episode psychosis
1 trial -
P160929J
Pari Pharma GmbH
Community acquired pneumonia (CAP)
1 trial -
PREDNISONE
Pari Pharma GmbH
Idiopathic retroperitoneal fibrosis
1 trial -
Regiocit solution pour hémofiltration
Pari Pharma GmbH
Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.
1 trial -
Repatha 140 mg solution for injection in pre-filled pen
Pari Pharma GmbH
acute myocardial infarction
1 trial -
Xolair 75 mg solution for injection in pre-filled syringe
Pari Pharma GmbH
Well controlled severe allergic asthma
1 trial
Frequently asked questions
How many clinical projects does PARItec have?
248 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.